Objective To explore the effect and toxicity of S -1 combined with oxaliplatin neoadjuvant chemotherapy in treatment of advanced gastric cancer.Methods 70 patients with gastric cancer were divided into the study group and the control group by using the random number table method,35 cases in each group.The study group was given neoadjuvant chemotherapy with S -1 combined with oxaliplatin,and the control group was treated with FOLFOX regimen.After three cycles of treatment,the effect and the toxicity of the two groups were observed and com-pared.Results The total effective rate of the study group was 71.43%,which was significantly higher than 45.71%(16 /35)of the control group (χ2 =5.02,P <0.05).The CD8 and CD4 /CD8 in the study group before and after radiotherapy had statistically significant difference (P <0.05 ).WBC and neutrophils in the control group had significant difference before and after treatment (P <0.05),CD8,CD4 /CD8 in the study group were significantly higher than those in control group (P <0.05).The incidence of gastrointestinal adverse reactions in the control group was significantly higher than that in the study group (χ2 =3.75.4.02,all P <0.05).The 1 year survival rate in the study group was 85.71%,2 years survival rate was 57.14%,the recurrence rates of 1 year and 2 years were 20.00%,40.00%,which in the control group were 71.43%,42.86%,22.86%,42.86%,the differences were not statistically significant (χ2 =1.02,0.79,0.90,1.05,all P >0.05).Conclusion S -1 combined with oxaliplatin neoadjuvant chemotherapy has good effect in treatment of advanced gastric cancer,the side reaction is small,with high safety.

ObjectiveTo investigate the influence of olsalazine on tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in patients with chronic ulcerative colitis.MethodsSixty patients with chronic ulcerative colitis(observation group),including 22 chronic recurrent cases and 38 chronic persistent cases,were enrolled and treated with olsalazine.Meanwhile,60 healthy volunteers without disease history of ulcerative colitis were selected as control group.The concentrations of TNF- α and IL-10 in serum of the two groups were detected by ELISA and compared.ResultsBefore treatment,the concentration of TNF- α in serum of the observation group was significantly higher than that of control group [ (57.2 ± 10.1 )ng/L vs.(27.2 ± 6.9) ng/L],while IL-10 was significantly lower than that of control group[ (9.2 ± 2.1 ) ng/L vs.(17.3 ±2.9) ng/L] (P ＜0.05).Before treatment,the concentration of TNF-α in serum in chronic persistent patients and chronic recurrent patients[ (56.9 ± 9.9),(57.3 ± 9.7) ng/L ] were significantly higher than that in control group,and serum IL-10 in chronic persistent patients and chronic recurrent patients [ (9.1 ± 2.3 ),(8.4 ± 2.5 ) ng/L ] was significantly lower than that in control group (P＜ 0.05 ).The concentration of TNF- α in serum in observation group after treatment was obviously lower than that before treatment [(28.1 ±8.9) ng/L vs.(57.2 ± 10.1 ) ng/L],and IL-10 was obviously higher than that before treatment [(13.4 ± 10.7) ng/L vs.(9.2 ±2.1 )ng/L] (P ＜ 0.05).The concentration of serum TNF-αand IL-10 in chronic persistent and chronic recurrent patients before and after treatment had statistical significance (P＜0.05 ).ConclusionsOlsalazine can significantly decrease the concentration of TNF- α and increase the concentration of IL-10 in serum in patients with chronic ulcerative colitis.It is worthy of application in clinic.